The long-term β2AR agonist formoterol, which is currently in use as bronchodilator in COPD, shows anti-proliferative activities in human airway smooth muscle cells and bronchus fibroblasts [9,14]. Here, ADRB2 is linked to chronic obstructive pulmonary disease.